Profilo
Dr. Evy Lundgren-Åkerlund is a CEO, Head-Business & Administration at Xintela AB.
She is on the Board of Directors at Targinta AB.
Dr. Lundgren-Åkerlund was previously employed as a Chief Executive Officer & Head-Operations by Lund Life Science Incubator and a Vice President-Research & Development by Cartela AB.
Posizioni attive di Evy Lundgren-Åkerlund
| Società | Posizione | Inizio |
|---|---|---|
| XINTELA AB | Fondatore | 01/01/2009 |
Targinta AB
 Targinta AB BiotechnologyHealth Technology Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Evy Lundgren-Åkerlund
| Società | Posizione | Fine |
|---|---|---|
| Lund Life Science Incubator | Amministratore Delegato | 01/01/2012 |
Cartela AB
 Cartela AB Pharmaceuticals: MajorHealth Technology Cartela AB develops therapies for arthritic diseases. It products are mainly used by osteoarthritis and rheumatoid arthritis. Its business is based on the cell surface molecules, integrants a10ß1 and a11ß1. The company was founded by Evy Lundgren-Åkerlund and Donald Gullberg in 2000 and is headquartered in Lund, Sweden. | Fondatore | 24/12/2008 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| XINTELA AB | Health Technology |
| Aziende private | 3 |
|---|---|
Cartela AB
Cartela AB Pharmaceuticals: MajorHealth Technology Cartela AB develops therapies for arthritic diseases. It products are mainly used by osteoarthritis and rheumatoid arthritis. Its business is based on the cell surface molecules, integrants a10ß1 and a11ß1. The company was founded by Evy Lundgren-Åkerlund and Donald Gullberg in 2000 and is headquartered in Lund, Sweden. | Health Technology |
| Lund Life Science Incubator | |
Targinta AB
Targinta AB BiotechnologyHealth Technology Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022. | Health Technology |
- Borsa valori
- Insiders
- Evy Lundgren-Åkerlund
